ENOVIS CORP (ENOV) Fundamental Analysis & Valuation

NYSE:ENOV • US1940141062

25.79 USD
+0.5 (+1.98%)
At close: Mar 4, 2026
25.79 USD
0 (0%)
After Hours: 3/4/2026, 8:21:56 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ENOV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Taking everything into account, ENOV scores 4 out of 10 in our fundamental rating. ENOV was compared to 184 industry peers in the Health Care Equipment & Supplies industry. ENOV has a medium profitability rating, but doesn't score so well on its financial health evaluation. ENOV is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

4

1. ENOV Profitability Analysis

1.1 Basic Checks

  • In the past year ENOV was profitable.
  • In the past year ENOV had a positive cash flow from operations.
  • ENOV had negative earnings in 4 of the past 5 years.
  • ENOV had a positive operating cash flow in 4 of the past 5 years.
ENOV Yearly Net Income VS EBIT VS OCF VS FCFENOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500M -1B

1.2 Ratios

  • ENOV has a Return On Assets of -30.89%. This is comparable to the rest of the industry: ENOV outperforms 40.76% of its industry peers.
  • ENOV has a Return On Equity (-79.51%) which is comparable to the rest of the industry.
  • ENOV has a Return On Invested Capital of 0.46%. This is in the better half of the industry: ENOV outperforms 66.30% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ENOV is significantly below the industry average of 8.90%.
  • The last Return On Invested Capital (0.46%) for ENOV is above the 3 year average (0.36%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -30.89%
ROE -79.51%
ROIC 0.46%
ROA(3y)-16.37%
ROA(5y)-9.72%
ROE(3y)-37.57%
ROE(5y)-22.31%
ROIC(3y)0.36%
ROIC(5y)N/A
ENOV Yearly ROA, ROE, ROICENOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60

1.3 Margins

  • ENOV has a Operating Margin of 0.84%. This is in the better half of the industry: ENOV outperforms 66.30% of its industry peers.
  • ENOV's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 58.16%, ENOV is in line with its industry, outperforming 58.70% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ENOV has grown nicely.
Industry RankSector Rank
OM 0.84%
PM (TTM) N/A
GM 58.16%
OM growth 3YN/A
OM growth 5Y-34.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.43%
GM growth 5Y6.64%
ENOV Yearly Profit, Operating, Gross MarginsENOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ENOV Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ENOV is destroying value.
  • Compared to 1 year ago, ENOV has more shares outstanding
  • The number of shares outstanding for ENOV has been increased compared to 5 years ago.
  • Compared to 1 year ago, ENOV has a worse debt to assets ratio.
ENOV Yearly Shares OutstandingENOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
ENOV Yearly Total Debt VS Total AssetsENOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • ENOV has an Altman-Z score of 0.63. This is a bad value and indicates that ENOV is not financially healthy and even has some risk of bankruptcy.
  • ENOV has a Altman-Z score of 0.63. This is comparable to the rest of the industry: ENOV outperforms 49.46% of its industry peers.
  • ENOV has a debt to FCF ratio of 65.11. This is a negative value and a sign of low solvency as ENOV would need 65.11 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 65.11, ENOV is doing good in the industry, outperforming 66.85% of the companies in the same industry.
  • ENOV has a Debt/Equity ratio of 0.85. This is a neutral value indicating ENOV is somewhat dependend on debt financing.
  • ENOV's Debt to Equity ratio of 0.85 is on the low side compared to the rest of the industry. ENOV is outperformed by 72.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 65.11
Altman-Z 0.63
ROIC/WACC0.06
WACC8.29%
ENOV Yearly LT Debt VS Equity VS FCFENOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

  • A Current Ratio of 2.02 indicates that ENOV has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.02, ENOV is doing worse than 61.41% of the companies in the same industry.
  • ENOV has a Quick Ratio of 1.04. This is a normal value and indicates that ENOV is financially healthy and should not expect problems in meeting its short term obligations.
  • ENOV has a Quick ratio of 1.04. This is in the lower half of the industry: ENOV underperforms 76.09% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.04
ENOV Yearly Current Assets VS Current LiabilitesENOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ENOV Growth Analysis

3.1 Past

  • ENOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.61%, which is quite good.
  • The Earnings Per Share has been decreasing by -4.57% on average over the past years.
  • ENOV shows a small growth in Revenue. In the last year, the Revenue has grown by 6.66%.
  • ENOV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.05% yearly.
EPS 1Y (TTM)16.61%
EPS 3Y13.28%
EPS 5Y-4.57%
EPS Q2Q%-3.06%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y12.88%
Revenue growth 5Y-6.05%
Sales Q2Q%2.64%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.35% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 4.56% on average over the next years.
EPS Next Y9.27%
EPS Next 2Y10.94%
EPS Next 3Y11.35%
EPS Next 5YN/A
Revenue Next Year4.04%
Revenue Next 2Y4.8%
Revenue Next 3Y4.56%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ENOV Yearly Revenue VS EstimatesENOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B
ENOV Yearly EPS VS EstimatesENOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. ENOV Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 7.82 indicates a rather cheap valuation of ENOV.
  • ENOV's Price/Earnings ratio is rather cheap when compared to the industry. ENOV is cheaper than 98.37% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.03. ENOV is valued rather cheaply when compared to this.
  • A Price/Forward Earnings ratio of 7.15 indicates a rather cheap valuation of ENOV.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 98.37% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of ENOV to the average of the S&P500 Index (25.11), we can say ENOV is valued rather cheaply.
Industry RankSector Rank
PE 7.82
Fwd PE 7.15
ENOV Price Earnings VS Forward Price EarningsENOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ENOV is valued cheaper than 94.02% of the companies in the same industry.
  • 69.57% of the companies in the same industry are more expensive than ENOV, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 74.13
EV/EBITDA 8.74
ENOV Per share dataENOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.84
PEG (5Y)N/A
EPS Next 2Y10.94%
EPS Next 3Y11.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ENOV Dividend Analysis

5.1 Amount

  • No dividends for ENOV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENOV Fundamentals: All Metrics, Ratios and Statistics

ENOVIS CORP

NYSE:ENOV (3/4/2026, 8:21:56 PM)

After market: 25.79 0 (0%)

25.79

+0.5 (+1.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners117.36%
Inst Owner Change0.03%
Ins Owners1.14%
Ins Owner Change0.32%
Market Cap1.48B
Revenue(TTM)2.25B
Net Income(TTM)-1.18B
Analysts84.44
Price Target46.36 (79.76%)
Short Float %15.5%
Short Ratio7.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.33%
Min EPS beat(2)13.32%
Max EPS beat(2)13.35%
EPS beat(4)4
Avg EPS beat(4)10.31%
Min EPS beat(4)6.8%
Max EPS beat(4)13.35%
EPS beat(8)8
Avg EPS beat(8)8.3%
EPS beat(12)12
Avg EPS beat(12)8.63%
EPS beat(16)16
Avg EPS beat(16)9.44%
Revenue beat(2)0
Avg Revenue beat(2)-1.7%
Min Revenue beat(2)-3.32%
Max Revenue beat(2)-0.09%
Revenue beat(4)0
Avg Revenue beat(4)-1.4%
Min Revenue beat(4)-3.32%
Max Revenue beat(4)-0.09%
Revenue beat(8)1
Avg Revenue beat(8)-1.24%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)0%
PT rev (3m)-9.09%
EPS NQ rev (1m)1.17%
EPS NQ rev (3m)1.34%
EPS NY rev (1m)0.05%
EPS NY rev (3m)-2.1%
Revenue NQ rev (1m)0.37%
Revenue NQ rev (3m)0.42%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-1.55%
Valuation
Industry RankSector Rank
PE 7.82
Fwd PE 7.15
P/S 0.66
P/FCF 74.13
P/OCF 6.79
P/B 0.99
P/tB N/A
EV/EBITDA 8.74
EPS(TTM)3.3
EY12.8%
EPS(NY)3.61
Fwd EY13.98%
FCF(TTM)0.35
FCFY1.35%
OCF(TTM)3.8
OCFY14.72%
SpS39.27
BVpS26.02
TBVpS-8.13
PEG (NY)0.84
PEG (5Y)N/A
Graham Number43.95
Profitability
Industry RankSector Rank
ROA -30.89%
ROE -79.51%
ROCE 0.58%
ROIC 0.46%
ROICexc 0.46%
ROICexgc 1.19%
OM 0.84%
PM (TTM) N/A
GM 58.16%
FCFM 0.89%
ROA(3y)-16.37%
ROA(5y)-9.72%
ROE(3y)-37.57%
ROE(5y)-22.31%
ROIC(3y)0.36%
ROIC(5y)N/A
ROICexc(3y)0.36%
ROICexc(5y)N/A
ROICexgc(3y)1.26%
ROICexgc(5y)N/A
ROCE(3y)0.45%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-36.37%
ROICexc growth 3YN/A
ROICexc growth 5Y-29.16%
OM growth 3YN/A
OM growth 5Y-34.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.43%
GM growth 5Y6.64%
F-Score4
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.85
Debt/FCF 65.11
Debt/EBITDA 4.03
Cap/Depr 67.05%
Cap/Sales 8.78%
Interest Coverage 0.69
Cash Conversion 69.38%
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.04
Altman-Z 0.63
F-Score4
WACC8.29%
ROIC/WACC0.06
Cap/Depr(3y)62.27%
Cap/Depr(5y)54.89%
Cap/Sales(3y)8.17%
Cap/Sales(5y)7.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.61%
EPS 3Y13.28%
EPS 5Y-4.57%
EPS Q2Q%-3.06%
EPS Next Y9.27%
EPS Next 2Y10.94%
EPS Next 3Y11.35%
EPS Next 5YN/A
Revenue 1Y (TTM)6.66%
Revenue growth 3Y12.88%
Revenue growth 5Y-6.05%
Sales Q2Q%2.64%
Revenue Next Year4.04%
Revenue Next 2Y4.8%
Revenue Next 3Y4.56%
Revenue Next 5YN/A
EBIT growth 1Y53.77%
EBIT growth 3YN/A
EBIT growth 5Y-38.41%
EBIT Next Year53.87%
EBIT Next 3Y21.57%
EBIT Next 5YN/A
FCF growth 1Y129.63%
FCF growth 3YN/A
FCF growth 5Y-36.11%
OCF growth 1Y91.44%
OCF growth 3YN/A
OCF growth 5Y-6.37%

ENOVIS CORP / ENOV FAQ

What is the ChartMill fundamental rating of ENOVIS CORP (ENOV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ENOV.


What is the valuation status of ENOVIS CORP (ENOV) stock?

ChartMill assigns a valuation rating of 8 / 10 to ENOVIS CORP (ENOV). This can be considered as Undervalued.


Can you provide the profitability details for ENOVIS CORP?

ENOVIS CORP (ENOV) has a profitability rating of 4 / 10.


What is the earnings growth outlook for ENOVIS CORP?

The Earnings per Share (EPS) of ENOVIS CORP (ENOV) is expected to grow by 9.27% in the next year.